(19)
(11) EP 1 292 668 A2

(12)

(88) Date of publication A3:
25.04.2002

(43) Date of publication:
19.03.2003 Bulletin 2003/12

(21) Application number: 01916144.7

(22) Date of filing: 20.02.2001
(51) International Patent Classification (IPC)7: C12N 1/15, C12N 15/10, C12N 15/80, C12N 15/90, C12N 15/65, C07K 14/40, C12P 21/00, A61K 39/00, C07K 16/14, G01N 33/50
(86) International application number:
PCT/US0105/551
(87) International publication number:
WO 0106/0975 (23.08.2001 Gazette 2001/34)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 18.02.2000 US 183534 P

(71) Applicant: Elitra Pharmaceuticals, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • ROEMER, Terry
    Montreal, Quebec H4V 1X4 (CA)
  • JIANG, Bo
    Montreal, Quebec H3W 2E6 (CA)
  • BOONE, Charles
    Toronto, Ontario M4T 1K9 (CA)
  • BUSSEY, Howard
    Westmount, Quebec H3Z 2N1 (CA)

(74) Representative: Horner, Martin Grenville et al
Cruikshank & Fairweather19 Royal Exchange Square
Glasgow G1 3AEScotland
Glasgow G1 3AEScotland (GB)

   


(54) GENE DISRUPTION METHODOLOGIES IN FUNGI FOR DRUG TARGET DISCOVERY